Editor, leitor
374
edições
Alterações
→Referências
3. Ohno-Matsui K. Pathologic myopia. Asia Pac J Ophthalmol 2016;5: 415–423.
4. Wong YL, Sabanayagam C, Ding Y et al. Prevalence, Risk Factors, and Impact of Myopic Macular Degeneration on Visual Impairment and Functioning Among Adults in Singapore. Invest Ophthalmol Vis Sci. 2018 Sep 4;59(11):4603.
5. Wong TY, Ferreira A, Hughes R et al. Epidemiology and Disease Burden of Patholoic Myopia and Myopic Choroidal Neovascularization: An Evidence Based Systemic Review. American Journal of Ophthalmology. 2014; 15:9-25.
6. Ruiz-Medrano J, Montero JA, Flores-Moreno I, et al. Myopic maculopathy: current status and proposal for a new classification and grading system (ATN). Prog Retin Eye Res. 2019 Mar;69:80-115
7. Wong YL, Hysi P, Cheung G, Tedja M, Hoang QV, Tompson SWJ, et al. (2019) Genetic variants linked to myopic macular degeneration in persons with high myopia: CREAM Consortium. PLoS ONE 14(8): e0220143.
8. Adatia FA, Luong M, Munro M et al. “The Other CNV: A review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents.” Survey of Ophthalmology. 2015 60; 204-215. Epub 2014